A s we all know, the anxiety disorders are the most ubiquitous of all psychiatric maladies. Yet they are relatively under-researched in Australia and educational activities in our region seldom have the anxiety disorders as their primary focus. Part of the reason for this is that there have been only a paltry trickle of new medications for the anxiety disorders and those that have eventuated have either been disappointing in clinical practice (such as buspirone), have seen anxiety indications as a slow second to depression or other indications (the selective serotonin reuptake inhibitors, the serotonin noradrenaline reuptake inhibitors, quetiapine), or have been a retro-fit of medications established for non-psychiatric indications and thus usually out of patent and of little commercial-and hence research or promotional-interest (eg. ondansetron or memantine for obsessive-compulsive disorder (OCD), pregabalin for generalised anxiety disorder (GAD)).
Another problem for the anxiety disorders has been the tendency to view them as being at the bottom of the hierarchical pyramid. This situation often leaves them as residual symptom sets, which can be forgotten by the clinician or attributed to disorders higher up the pyramid (eg. social withdrawal in schizophrenia being dismissed as negative symptoms whereas a number of individuals would have comorbid social anxiety disorder). Whilst in many ways the latest edition of the US-dominant Diagnostic and statistical manual of mental disorders (DSM-5) 1 is a rather sorry tale of overenthusiastic reductionism and a quest for certainty in an uncertain field (the progenitors would do well to remind themselves that anxiety is actually a good thing in many ways and keeps the clinician on their toes and truly responsive to the changing and nuanced needs of individual patients), the tinkering with the anxiety disorders is actually a half-sensible advance in most areas (albeit a mess in others), from Diagnostic and statistical manual of mental disorders, 4 th edition (DSM-IV). 2 In particular, the disaggregation of the 'core' anxiety disorders from the post-traumatic syndromes and the obsessive-compulsive and related syndromes does have some veracity in terms of both clinical practice and research and is useful enough heuristically.
However, there are some exciting developments in the anxiety disorder field and it is wonderful that good research is being undertaken in Australia and New Zealand in various domains. The selection of articles in this edition of Australasian Psychiatry is testament to that, and provides a broad sweep of some of these endeavours. Most are based on papers presented at a conference of the International Society for Anxiety Disorders held in Melbourne in late 2014 and it is wonderful that the editor of this journal led the idea of bringing them together in this single edition. Nicely, there is also a set of articles on the post-traumatic syndromes, coincident with and focused upon the Australian and New Zealand Army Corps (ANZAC) experience in this 100 th anniversary year of the Gallipoli landings. Additionally, there are articles about irritable bowel syndrome and inflammatory bowel disease, in both of which the links between mind and body are made explicit.
The spread of published articles is broad. Starcevic 3 reviews GAD, which in many ways has become a rump disorder, which is what is left behind when the phobic disorders and panic disorder are taken away. GAD was nearly lost into the morass of the depressive disorders, but was then briefly expanded in concept by the DSM-5 process until the field trials showed such pathetic lack of reliability that DSM-5 reverted to a definition of GAD very similar to DSM-IV. There remains a problem with different conceptualisations of GAD in the US (a 'worry disorder') and Europe (an 'autonomic disorder'). It will be interesting to see how the International classification of diseases, 11 th revision (ICD-11) deals with this tension.
Of the phobic disorders, Lampe 4 looks at social anxiety disorder and asks whether it is the same as avoidant personality disorder. This is a nice example of teasing at what used to be the Axis I vs. Axis II debate until the American Psychiatric Association scrapped the axes Editorial altogether. However, the issue remains highly pertinent, as early onset severe social anxiety disorder can look very much like avoidant personality disorder but requires different therapeutic approaches.
A group of articles then addresses various aspects of the so-called obsessive-compulsive spectrum (OCS). Core articles by Castle et al. 5 and Crino 6 address pharmacological and psychological treatment approached to OCD itself, albeit both articles stress that the treatment must be holistic and encompass both psychosocial and biological parameters. A case in point is the very exciting use of deep brain stimulation in OCD, where psychological support and ongoing OCD-focused treatment is crucial to success, as is assisting the patient and their family come to terms with and adapt to life beyond the tyranny of OCD.
Of the OCS disorders, it is arguably body dysmorphic disorder (BDD) that has the most robust claim to membership. However, there are substantial differences between BDD and OCD at the phenomenological, neurobiological, and therapeutic levels. Rossell et al. 7 review a series of experiments addressing the neurobiology of BDD and make linkages to therapeutic endeavours for this often tricky disorder.
Further within the OCS disorders, Snowden 8 interrogates when hoarding behaviour should be considered a disorder, and Brakoulias 9 provides useful pointers regarding assessment and treatment of hoarding disorder. Rehm 10 then tackles the notoriously difficult-to-treat trichotillomania, for which medication if usually not helpful; her work tries to understand the disorder in psychological terms to inform more nuanced treatments than simply habit reversal.
Another set of articles deals with comorbidity. Of course, we all know how rare it is to find patients with 'pure' DSM-defined disorders and it is imperative that clinicians appreciate and address the complex array of comorbid symptoms and behaviours associated with psychiatric disturbances. Bosanac et al. 11 deal with these issues as they pertain to people with schizophrenia, whilst Kuiper 12 and Arunogiri 13 do likewise for bipolar disorder and substance abuse, respectively. These are highly clinically relevant and applicable articles that I am confident will be of use to all mental health professionals.
As stated above, there is a fortunate co-publication with the anxiety disorder conference articles, of three pieces addressing various aspects of the response to traumamilitary-related trauma, in this instance. Hence, McLeod 14 reviews Australian contributions to the literature of 'shell shock' in World War I and McFarlane 15 provides a broader perspective on the last 100 years of war-related trauma in psychiatry. Berle 16 reminds us of the impact of war on the families of returned servicemen, an oft forgotten component of the suffering engendered by military conflict.
Finally, Keightly 17, 18 pens two nice pieces entitled 'gut feelings', addressing psychological and psychiatric aspects of irritable bowel syndrome and inflammatory bowel disease. This reminds us of the complex and profound interactions between mind and body and fits well with the general theme of this issue of Australasian Psychiatry.
Although I started off perhaps negatively, after writing this piece, I feel rather buoyed by the knowledge that many fine minds in our countries are continuing to advance the field of anxiety disorders and to help lead us to better understandings and treatments. Hood 19 provides a synopsis of management guidelines as discussed in a workshop at the conference. It makes me think we should consider a more strategic alignment of work in the field and perhaps create a section within our college to this end. If anyone has any views about this and/or is interested in being part of such an initiative, please email me on david.castle@svha.org.au.
